Tirofiban for Successful Endovascular Stroke Thrombectomy

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 712 participants.

Also called NCT06373042

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 712 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06373042
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06373042. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-31 (anticipated); primary completion 2026-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tirofiban for Successful Endovascular Stroke Thrombectomy
Acronym
ADJUVANT-2
Condition
Stroke, Acute Ischemic
Intervention (Drug)
Intraarterial and intravenous tirofiban
Intervention (Drug)
Intraarterial and intravenous placebo
Lead sponsor
Zhongming Qiu (class: other)
Collaborator
Mianyang Central Hospital (class: other)
Collaborator
The Second Affiliated Hospital of Chongqing Medical University (class: other)
Collaborator
The Second Hospital of Jiaozuo (class: not stated)
Collaborator
Chongzhou People's Hospital (class: not stated)
Collaborator
Xihua First Hospital (class: other)
Collaborator
Xingguo People's Hospital (class: not stated)

Record details

Record id
cardio:ct-nct06373042
Content hash
61416cf821b8e8cefddbd94713f18efa8f441f7364e0277fe8a5c1b16cff3cea